Tocilizumab Real-Life Human Factors (RLHFs) Validation Study
22 de janeiro de 2019 atualizado por: Hoffmann-La Roche
Tocilizumab Real-Life Human Factors Validation Study
This study is designed to evaluate RLHFs concerning administration of the tocilizumab autoinjector AI-1000 G2 in adults with rheumatoid arthritis (RA) who have been receiving subcutaneous (SC) tocilizumab using the commercially available prefilled syringe and needle safety device (PFS-NSD).
The study will enroll participants with RA, a subset of whom will be assigned to perform self-injection with the AI-1000 G2.
Enrolled caregivers (CGs) and healthcare professionals (HCPs) will administer the AI-1000 G2 injection to the remaining study participants.
Visão geral do estudo
Status
Concluído
Condições
Intervenção / Tratamento
Tipo de estudo
Intervencional
Inscrição (Real)
91
Estágio
- Fase 4
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Locais de estudo
-
-
Arizona
-
Mesa, Arizona, Estados Unidos, 85202
- Arizona Arthritis and Rheuma
-
-
California
-
Los Alamitos, California, Estados Unidos, 90720
- Valerius Medical Group & Research Ctr of Greater Long Beach
-
Santa Maria, California, Estados Unidos, 93454
- Pacific Arthritis Ctr Med Grp
-
-
Kentucky
-
Lexington, Kentucky, Estados Unidos, 40515
- Bluegrass Comm Research, Inc.
-
-
Oklahoma
-
Tulsa, Oklahoma, Estados Unidos, 74104
- Oklahoma Center For Arthritis Therapy & Research
-
-
Pennsylvania
-
Duncansville, Pennsylvania, Estados Unidos, 16635
- Altoona Center for Clinical Research
-
Wexford, Pennsylvania, Estados Unidos, 15090
- Advanced Rheumatology & Arthritis Research Center
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75231
- Metroplex Clinical Research
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
18 anos e mais velhos (Adulto, Adulto mais velho)
Aceita Voluntários Saudáveis
Não
Gêneros Elegíveis para o Estudo
Tudo
Descrição
Inclusion Criteria:
- Participants with RA for greater than or equal to (>/=6) months receiving 162 mg tocilizumab PFS-NSD for >/=8 weeks and who are suitable for continued treatment at their currently prescribed dose
- CGs and professionally qualified HCPs who are able and willing to administer the injection
Exclusion Criteria:
- RA: Functional status Class IV
- RA: Neuropathies or other conditions that might interfere with pain evaluation
- RA: Pregnant or breastfeeding
- RA: Low neutrophil or platelet count at last laboratory assessment
- RA: Elevated liver enzymes at last laboratory assessment
- Current participation in another interventional clinical trial
- Criteria that might give the participant/CG/HCP an advantage in injection tasks such as employment in the pharmaceutical industry, etc.
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Viabilidade do dispositivo
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Caregivers
CGs will perform injection of SC tocilizumab to a subset of participants with RA using the AI-1000 G2 device.
Visit 1 (Day 0) will be conducted for administration training, while Visits 2 and 3 (Days 14 and 28) will be conducted for use/performance evaluation.
|
Tocilizumab will be administered using the AI-1000 G2.
Participants will receive three doses of SC tocilizumab using the AI-1000 G2 device at Visits 1, 2, and 3 (Days 0, 14, and 28).
The dose will remain at 162 milligrams (mg) unless changes are required per protocol for safety or efficacy reasons.
Outros nomes:
|
|
Experimental: Healthcare Professionals
HCPs will perform injection of SC tocilizumab to a subset of participants with RA using the AI-1000 G2 device.
Because enrolled HCPs are to be professionally qualified to deliver SC injections, no administration training will be provided.
Visits 2 and 3 (Days 14 and 28) will be conducted for use/performance evaluation.
|
Tocilizumab will be administered using the AI-1000 G2.
Participants will receive three doses of SC tocilizumab using the AI-1000 G2 device at Visits 1, 2, and 3 (Days 0, 14, and 28).
The dose will remain at 162 milligrams (mg) unless changes are required per protocol for safety or efficacy reasons.
Outros nomes:
|
|
Experimental: RA Group 1 (Self-Administration)
Participants with RA will perform self-injection of SC tocilizumab with the AI-1000 G2 device.
Visit 1 (Day 0) will be conducted for administration training, while Visits 2 and 3 (Days 14 and 28) will be conducted for use/performance evaluation.
|
Tocilizumab will be administered using the AI-1000 G2.
Participants will receive three doses of SC tocilizumab using the AI-1000 G2 device at Visits 1, 2, and 3 (Days 0, 14, and 28).
The dose will remain at 162 milligrams (mg) unless changes are required per protocol for safety or efficacy reasons.
Outros nomes:
|
|
Outro: RA Group 2 (Administration by CG)
CGs will perform injection of SC tocilizumab to participants with RA using the AI-1000 G2 device.
Visit 1 (Day 0) will be conducted for administration training, while Visits 2 and 3 (Days 14 and 28) will be conducted for use/performance evaluation.
|
Tocilizumab will be administered using the AI-1000 G2.
Participants will receive three doses of SC tocilizumab using the AI-1000 G2 device at Visits 1, 2, and 3 (Days 0, 14, and 28).
The dose will remain at 162 milligrams (mg) unless changes are required per protocol for safety or efficacy reasons.
Outros nomes:
|
|
Outro: RA Group 3 (Administration by HCP)
HCPs will perform injection of SC tocilizumab to participants with RA using the AI-1000 G2 device.
Because enrolled HCPs are to be professionally qualified to deliver SC injections, no administration training will be provided.
Visit 1 (Day 0) will be performed by the study nurse.
Visits 2 and 3 (Days 14 and 28) will be conducted by the HCP for use/performance evaluation.
|
Tocilizumab will be administered using the AI-1000 G2.
Participants will receive three doses of SC tocilizumab using the AI-1000 G2 device at Visits 1, 2, and 3 (Days 0, 14, and 28).
The dose will remain at 162 milligrams (mg) unless changes are required per protocol for safety or efficacy reasons.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Percentage of Participants Who Successfully Performed Safety-Critical and Essential Tasks During First Unassisted Use
Prazo: Day 14
|
Safety-critical tasks included those tasks where errors would have a reasonably foreseeable potential for clinical impact/harm, potentially resulting in direct physical injury to the user and/or conditions that require medical intervention.
Safety-critical tasks included the following: release activation button; check the expiry date; inspect device prior to use; and inspect medication prior to use.
Essential tasks included those essential to the execution of the injection.
Essential tasks included the following: open the carton, remove the device and associated documents; remove cap; start an injection by depressing the needle-shield at the injection site and pressing the activation button; and hold the autoinjector until the complete dose has been delivered.
The percentage of participants who successfully performed safety-critical and essential tasks during the first unassisted use (Day 14) was reported.
|
Day 14
|
|
Percentage of Participants Who Successfully Performed Safety-Critical and Essential Tasks During Second Unassisted Use
Prazo: Day 28
|
Safety-critical tasks included those tasks where errors would have a reasonably foreseeable potential for clinical impact/harm, potentially resulting in direct physical injury to the user and/or conditions that require medical intervention.
Safety-critical tasks included the following: release activation button; check the expiry date; inspect device prior to use; and inspect medication prior to use.
Essential tasks included those essential to the execution of the injection.
Essential tasks included the following: open the carton, remove the device and associated documents; remove cap; start an injection by depressing the needle-shield at the injection site and pressing the activation button; and hold the autoinjector until the complete dose has been delivered.
The percentage of participants who successfully performed safety-critical and essential tasks during the second unassisted use (Day 28) was reported.
|
Day 28
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Percentage of Participants Who Successfully Performed Ancillary Tasks During First and Second Unassisted Use
Prazo: Days 14, 28
|
Ancillary tasks included those tasks where the potential harm resulting from use error would be minor in severity, or the resultant harms were estimated to occur at sufficiently low levels.
Ancillary tasks included the following: wash hands; clean the injection site with alcohol swab; wait for the alcohol to dry; dispose of the autoinjector cap; inspect full dose delivered after use; dispose of the autoinjector; and treatment of injection site after injection.
The percentage of participants who succesffully performed ancillary tasks during the first (Day 14) and second unassisted use (Day 28) was reported.
|
Days 14, 28
|
|
Visual Analog Scale (VAS) Score for Injection Pain Among Participants With RA
Prazo: 0 and 15 minutes after injection on Days 0, 14, 28
|
Injection pain was assessed on a continuous 100-millimeter (mm) VAS, where 0 mm represents "no pain" and 100 mm represents "unbearable pain".
The mean VAS response at each assessment timepoint was reported among participants with RA.
|
0 and 15 minutes after injection on Days 0, 14, 28
|
|
Percentage of Participants by Response to Categorical Scale of Injection Pain Among Participants With RA
Prazo: 0 and 15 minutes after injection on Days 0, 14, 28
|
Injection pain was assessed on a categorical 6-point Likert scale, ranging from "no pain" to "severe and intolerable".
The percentage of participants was reported by response at each assessment timepoint among participants with RA.
|
0 and 15 minutes after injection on Days 0, 14, 28
|
|
Percentage of Participants by Response to Device Satisfaction Questionnaire
Prazo: Days 0, 14, 28
|
Device satisfaction was assessed using twelve questions on a categorical 5-point Likert scale, ranging from "strongly agree" to "strongly disagree".
Question (Q) 1 (felt the autoinjection was easy to use), Q2 (felt comfortable while using the autoinjector), Q3 (felt the autoinjector was easy to hold), Q4 (able to tell when injection had completed), Q5 (felt he/she can inject properly with the autoinjector), Q6 (felt he/she had control over the injection process), Q7 (felt confident that he/she injected successfully), Q8 (felt it is easy to dispose of the autoinjector), Q9 (autoinjector would help to manage his/her injection schedule), Q10 (liked the look/feel of the autoinjector), Q11 (would recommend the autoinjector to someone else who needed to inject), Q12 (would continue having injections with the autoinjector).
The percentage of participants was reported by response at each assessment among participants with RA, CGs, and HCPs.
|
Days 0, 14, 28
|
|
Tender Joint Count (TJC) Among Participants With RA
Prazo: Baseline (Day 0)
|
Sixty-eight joints were assessed for tenderness among participants with RA.
The number of tender joints at Baseline was reported.
|
Baseline (Day 0)
|
|
Swollen Joint Count (SJC) Among Participants With RA
Prazo: Baseline (Day 0)
|
Sixty-six joints were assessed for swelling among participants with RA.
The number of swollen joints at Baseline was reported.
|
Baseline (Day 0)
|
|
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Among Participants With RA
Prazo: Days 0, 14, 28
|
Ability to perform daily living activities was assessed across eight component sets including dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common activities.
Twenty questions were scored on a 4-point Likert scale from 0 meaning "without any difficulty" to 3 meaning "unable to do".
The overall score was computed as the sum of domain scores divided by the number of domains answered.
Therefore, the score range for HAQ-DI was the same as that of the individual questions, that is, from 0 to 3, where 0 indicates "least difficulty" and 3 indicates "extreme difficulty".
The mean change from baseline in HAQ-DI at each assessment was reported among participants with RA.
|
Days 0, 14, 28
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Publicações e links úteis
A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo (Real)
21 de março de 2016
Conclusão Primária (Real)
29 de julho de 2016
Conclusão do estudo (Real)
29 de julho de 2016
Datas de inscrição no estudo
Enviado pela primeira vez
11 de fevereiro de 2016
Enviado pela primeira vez que atendeu aos critérios de CQ
11 de fevereiro de 2016
Primeira postagem (Estimativa)
15 de fevereiro de 2016
Atualizações de registro de estudo
Última Atualização Postada (Real)
19 de abril de 2019
Última atualização enviada que atendeu aos critérios de controle de qualidade
22 de janeiro de 2019
Última verificação
1 de janeiro de 2019
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- WA29917
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Sim
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Não
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .